1-2 of 2
Antonio Rueda, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Risk Adapted-High Dose Therapies Modulate the Impact of Biological Classification in Diffuse Large B Cell Lymphoma Prognosis. Analysis of Biological Markers in Patients From Clinical Trials in Geltamo and Gotel Spanish Collaborative Groups.

Free
Santiago Montes-Moreno, Ana Batlle, MD, Sonia Gonzalez de Villambrosia, MD, Beatriz Sanchez-Espiridión, PhD, Laura Cereceda, Eva González-Barca, Purroy Noelia, MD, Emilia Pardal, Elena Sebastian, Alejandro Martin, Carlos Grande, Francisco Mazorra, MD, Andrés Insunza, Antonio Rueda, MD, Marta Llanos, MD, Jose Gomez Codina, MD, Francisco Ramon Garcia Arroyo, MD, Dolores Caballero, MD, Eulogio Conde, Andrés Lopez, MD, Mariano Provencio, Miguel Piris, MD
Journal: Blood
Blood (2012) 120 (21): 2672.
https://doi.org/10.1182/blood.V120.21.2672.2672
Published: 2012
Journal Articles

Mabthera (Rituximab) Plus CVP Chemotherapy for First-Line Treatment of Stage III/IV Follicular Non-Hodgkin’s Lymphoma (NHL): Confirmed Efficacy with Longer Follow-Up.

Free
Philippe Solal-Celigny, MD, Kevin Imrie, MD, Andrew Belch, MD, Katherine Sue Robinson, MD, David Cunningham, Antonio Rueda, MD, John Catalano, MD, Fritz Offner, Jan Walewski, MD, João Raposo, MD, Paul Smith, MSc, Robert Marcus, MD
Journal: Blood
Blood (2005) 106 (11): 350.
https://doi.org/10.1182/blood.V106.11.350.350
Published: 2005